Changing Treatment Landscape in the Initial Management of Metastatic Castrate-Resistant Prostate Cancer (mCRPC): An Australian Multi-Centre Retrospective Study

被引：0
|
作者：
Kwan, E. [1 ,2 ]
Semira, C. [3 ,4 ]
Muttiah, C. [5 ]
Beck, S. [3 ,4 ]
Anton, A. [4 ]
Tran, B. [3 ,4 ]
机构：
[1] Monash Hlth, Dept Med Oncol, Melbourne, Vic, Australia
[2] Monash Univ, Sch Clin Sci, Dept Med, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia
[4] Walter & Eliza Hall Inst Med Res, Div Syst Biol & Personalised Med, Melbourne, Vic, Australia
[5] Western Hlth, Dept Med Oncol, Melbourne, Vic, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：48 / 49
页数：2
相关论文
共 50 条
  • [1] Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
    Karnes, R. Jeffrey
    Ahmed, Mohamed E.
    APPLIED RADIOLOGY, 2021, 50 (01) : 42 - 43
  • [2] Genomic landscape of CDK12 mutated metastatic castrate-resistant prostate cancer (mCRPC).
    Grivas, Petros
    Bratslavsky, Gennady
    Jacob, Joseph M.
    Necchi, Andrea
    Spiess, Philippe E.
    Danziger, Natalie
    Huang, Richard
    Mata, Douglas A.
    Decker, Brennan James
    Sokol, Ethan
    Montesion, Meagan
    Tukachinsky, Hanna
    Venstrom, Jeffrey Michael
    Ross, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [3] Abiraterone for the Treatment of Metastatic Castrate-Resistant Prostate Cancer
    Beckett, Robert D.
    Rodeffer, Kathryn M.
    Snodgrass, Rachel
    ANNALS OF PHARMACOTHERAPY, 2012, 46 (7-8) : 1016 - 1024
  • [4] Exosomal microRNA as prognostic biomarkers in metastatic castrate-resistant prostate cancer (mCRPC).
    Kohli, Manish
    Huang, Xiaoyi
    Yuan, Tiezheng
    Sun, Zhifu
    Costello, Brian Addis
    Quevedo, Fernando
    Tan, Winston
    Nandy, Debashis
    Longenbach, Sherri
    Wang, Liang
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [5] Treatment sequencing in metastatic castrate-resistant prostate cancer
    Sartor, Oliver
    Gillessen, Silke
    ASIAN JOURNAL OF ANDROLOGY, 2014, 16 (03) : 426 - 431
  • [6] Impact of comorbidity on outcome in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Zist, A.
    Amir, E.
    Ocana, A.
    Seruga, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S703 - S703
  • [7] Enzalutamide after abiraterone in patients with metastatic castrate-resistant prostate cancer (mCRPC).
    Sandhu, Gurprataap Singh
    Parikh, Rahul Atul
    Appleman, Leonard Joseph
    Friedland, David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [8] Pembrolizumab (pembro) in heavily pretreated metastatic castrate-resistant prostate cancer (mCRPC).
    Moses, Marcus Marie
    Ledet, Elisa
    Manogue, Charlotte
    Lewis, Brian E.
    Barata, Pedro C.
    Sartor, A. Oliver
    Layton, Jodi Lyn
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [9] AUSTRALIAN EXPERIENCE WITH CABAZITAXEL IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER (mCRPC)
    Ng, S.
    Gurney, H.
    Parente, P.
    Bahre, M.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 63 - 63
  • [10] The Sequencing Conundrum in Metastatic Castrate-resistant Prostate Cancer (mCRPC): the Rosemere Cancer Centre Experience to Unlocking the Optimal Sequence
    Pan, S.
    Kumar, V.
    Charnley, N.
    Parikh, O.
    Birtle, A.
    CLINICAL ONCOLOGY, 2016, 28 (05) : E14 - E14
12345